(Albany, New York) – October 19, 2026 – The market dynamics for Anal Cancer are expected to witness significant growth, driven by the increasing disease burden, evolving treatment approaches, and the development of novel immunotherapies and combination therapies. Additionally, emerging therapies such as retifanlimab-dlwr (ZYNYZ), BMX-001, pelareorep in combination with atezolizumab, and others are expected to influence the market landscape.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Anal Cancer Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Anal Cancer, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Anal Cancer Market
According to DelveInsight, the Anal Cancer market size across the seven major markets (7MM) was approximately USD 12 million in 2025 and is projected to reach nearly USD 120 million by 2036, growing at a CAGR of approximately 24% during 2026–2036.
In 2025, the EU4 and the United Kingdom accounted for nearly 50% of the Anal Cancer market size among the 7MM.
According to DelveInsight estimates, there were nearly 20,500 incident cases of Anal Cancer in the 7MM in 2025, with the United States accounting for the highest number of cases.
In the EU4 and the United Kingdom, females accounted for nearly 70% of incident cases, compared with approximately 30% in males in 2025.
Leading companies developing therapies for Anal Cancer include Incyte Corporation, BioMimetix, Oncolytics Biotech, Bicara Therapeutics, and others.
Promising therapies covered in the market landscape include retifanlimab-dlwr (ZYNYZ), BMX-001, and pelareorep plus atezolizumab.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/anal-cancer-market
Key Factors Driving the Anal Cancer Market
Rising Disease Burden and Growing Recognition: Anal Cancer remains a relatively uncommon malignancy, but its incidence has increased over recent decades. Improved disease recognition, diagnostic approaches, and awareness of associated risk factors are contributing to the identification and management of affected patients.
Advancements in Immunotherapy and Combination Treatments: Immunotherapies and combination treatment approaches are expanding the therapeutic landscape for Anal Cancer. The development of treatments designed to improve clinical outcomes, particularly in patients with advanced or difficult-to-treat disease, is an important area of research.
Growing Focus on Unmet Medical Needs: Despite advances in treatment, patients with Anal Cancer continue to face challenges related to disease progression, treatment response, and advanced-stage disease. Continued research into novel mechanisms and combination strategies may help address these unmet medical needs and support future market growth.
Anal Cancer Competitive Landscape
Several companies are developing therapies for Anal Cancer, including Incyte Corporation, BioMimetix, Oncolytics Biotech, and Bicara Therapeutics.
Key therapies in the Anal Cancer treatment landscape include retifanlimab-dlwr (ZYNYZ), an immunotherapy targeting PD-1; BMX-001, an investigational manganese porphyrin-based therapeutic candidate; and pelareorep in combination with atezolizumab, an investigational combination approach involving an oncolytic virus and an immune checkpoint inhibitor.
These treatment approaches reflect ongoing efforts to improve outcomes for patients with Anal Cancer and expand the available therapeutic options.
Discover more about therapies set to shape the Anal Cancer market @ Anal Cancer Treatment Landscape
Recent Developments in the Anal Cancer Market
In August 2025, Invion Limited announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation to INV043 for the treatment of Anal Cancer.
What is Anal Cancer?
Anal Cancer is a relatively rare malignancy that develops in the tissues of the anus, the opening at the end of the rectum. Most cases originate in the squamous cells lining the anal canal and are associated with human papillomavirus (HPV) infection. The disease may present with symptoms such as rectal bleeding, pain, changes in bowel habits, or a lump near the anus. Diagnosis, disease stage, and tumor characteristics influence treatment decisions and clinical outcomes.
Anal Cancer Epidemiology Segmentation
The Anal Cancer epidemiology section provides insights into the historical and current Anal Cancer patient pool and forecasted trends across the leading markets. The Anal Cancer market report evaluates epidemiological trends over the study period 2022–2036 in the seven major markets (7MM).
The epidemiology analysis is segmented into:
Total Incident Cases of Anal Cancer
Gender-specific Cases of Anal Cancer
Age-specific Cases of Anal Cancer
Histology-specific Cases of Anal Cancer
HPV Status-specific Cases of Anal Cancer
Stage-specific Cases of Anal Cancer
Line-wise Treated Cases of Anal Cancer
Scope of the Anal Cancer Market Report
Therapeutic Assessment: Current treatment practices and emerging Anal Cancer therapies.
Anal Cancer Market Dynamics: Historical and forecasted market size, market share, treatment uptake, and market outlook.
Key Companies: Incyte Corporation, BioMimetix, Oncolytics Biotech, Bicara Therapeutics, and others.
Key Therapies: Retifanlimab-dlwr (ZYNYZ), BMX-001, pelareorep plus atezolizumab, and other relevant therapies.
Competitive Intelligence Analysis: Assessment of the competitive landscape, emerging therapies, and clinical development.
Unmet Needs and Market Assessment: Evaluation of treatment challenges, patient burden, market drivers, barriers, reimbursement, and opportunities for future growth.
To know more about Anal Cancer companies working in the treatment market, visit @ Anal Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
Anal Cancer Market Report Introduction
Executive Summary for Anal Cancer
Key Events and SWOT Analysis of Anal Cancer
Anal Cancer Patient Share (%) Overview at a Glance
Anal Cancer Market Overview at a Glance
Anal Cancer Background and Overview
Anal Cancer Epidemiology and Patient Population
Country-Specific Patient Population of Anal Cancer
Anal Cancer Current Treatment and Medical Practices
Anal Cancer Unmet Needs
Anal Cancer Emerging Therapies
Anal Cancer Market Outlook
Country-Wise Anal Cancer Market Analysis (2022–2036)
Anal Cancer Market Access and Reimbursement of Therapies
Anal Cancer Market Drivers
Anal Cancer Market Barriers
Anal Cancer Appendix
Anal Cancer Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
